Characteristic	Kahn 2006	Ko 2006	Lebovitz 2001	Ovalle 2004	Philipps 2001	Raskin 2004
	Kahn 2006 I1: rosiglitazone max. 8 mg C1: metformin max. 2 g C2: glyburide max. 15 mg	I1: rosiglitazone max. 8 mg + (sulfonylurea +/‐ metformin) C1: "bedtime insulin" + (sulfonylurea +/‐ metformin)	I1: rosiglitazone 4 mg I2: rosiglitazone 8 mg C1: placebo	I1: rosiglitazone 8 mg C1: insulin 70/30	I1: rosiglitazone 4 mg I2: rosiglitazone 2 x 2 mg I3: rosigllitazone 8 mg I4: rosiglitazone 2 x 4 mg C1: placebo	I1: rosiglitazone 8 mg C1: repaglinide 12 mg C2: rosiglitazone 4 mg + repaglinide 6 mg
Sex [%]	I1: female 44; male 56 C1: female 40; male 60 C2: female 42; male 58	I1: female 43; male 57 C1: female 57; male 43	I1: female 36; male 64 I2: female 33; male 67 C1: female 34; male 66	?	I1: female 41; male 59 I2: female 41; male 59 I3: female 34; male 66 I4: female 35; male 65 C1: female 31; male 69	I1: female 47; male 53 C1: female 38; male 62 C2: female 49; male 51
Age [years], mean (SD)	I1: 56.3 (10.0) C1: 57.9 (9.9) C2: 56.4 (10.2)	I1: 56.6 (10.7) C1: 59.8 (11.2)	I1: 60 (9.8) I2: 61 (9.5) C1: 59 (10.9)	I1: 47 (12) C1: 56 (14.1)	I1: 57.5 (9.9) I2: 56.8 (9.4) I3: 58.9 (9.9) I4: 56.5 (9.7) C1: 57.7 (9.2)	I1: 56.6 (10.8) C1: 58.5 (10.1) C2: 57.5 (10.8)
Ethnic groups [%]	I1: white 87; black 4; asian 3; hispanic 5; other 1 C1: white 89; black 4; asian 2; hispanic 4; other 1 C2: white 89; black 4; asian 2; hispanic 4; other 0.3	Chinese patients	I1: white 75; black 8; other 16 I2: white 73; black 9; other 17 C1: white 74; black 8; other 18	?	I1: white 76; black 13; other 11 I2: white 78; black 8; other 14 I3: white 80; black 7; other 13 I4: white 71; black 11; other 18 C1: white 79; black 9; other 12	I1: caucasian 68; black 13; hispanic 0; other 19 C1: caucasian 63; black 16; hispanic 2; other 19 C2: caucasian 65; black 17; hispanic 3; other 15
Duration of disease [years], mean (SD)	?	I1: 11.8 (7.7) C1: 13.6 (7.5)	I1: 4.8 (5.8) I2: 5.4 (6.0) C1: 4.6 (4.8)	I1: 7.6 (6.3) C1: 7.6 (4.8)	I1: 5.4 (6.1) I2: 5.5 (4.9) I3: 6.1 (6.7) I4: 5.9 (6.1) C1: 6.6 (6.9)	I1: 7.4 (6.6) C1: 7.2 (5.3) C2: 7.3 (6.9)
Body mass index [kg/m2], mean (SD)	I1: 32.2 (6.7) C1: 32.1 (6.1) C2: 32.2 (6.3)	I1: 25.3 (3.8) C1: 24.0 (2.7)	I1: 30.2 (4.1) I2: 29.1 (3.9) C1: 29.9 (4.1)	I1: 31.5 (6.9) C1: 30.8 (7.6)	I1: 29.9 (4.1) I2: 30.0 (4.2) I3: 30.0 (4.3) I4: 29.9 (4.3) C1: 29.1 (4.2)	I1: 31.4 (5.2) C1: 30.4 (4.7) C2: 32.3 (5.2)
Pharmaco‐naive patients [%]	I1: 100 C1: 100 C2: 100	?	I1: 26.5 I2: 26.6 C1: 28.5	I1: none C1: none	I1: 22.1 (40/181) I2: 24.7 (46/186) I3: 29.3 (53/181) I4: 25.1 (47/187) C1: 22.5 (39/173)	I1: none C1: none C2: none
HbA1c [%], mean (SD)	I1: 7.4 (0.9) C1: 7.4 (0.9) C2: 7.4 (0.9)	I1: 10.1 (1.0) C1: 9.6 (0.9)	I1: 9.0 (1.5) I2: 8.8 (1.6) C1: 9.0 (1.7)	I1: 8.7 C1: 9.0	I1: 8.9 (1.6) I2: 8.9 (1.5) I3:8.9 (1.5) I4:9.0 (1.5) C1: 8.9 (1.5)	I1: 9.0 C1: 9.3 C2: 9.1
Co‐morbidities [%]	?	?	?	?	?	?
Notes	antihypertensive therapy: I1: 51%; C1: 51%; C2: 52%	antihypertensive agents: I1: 55%; C1: 25% lipid‐lowering agents: I1: 9%; C1: 4%	ITT population	SDs calculated	ITT population	./.
Footnotes ? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention‐to‐treat